LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・Alkermes PLC

Alkermes PLC

Closed

SectorHealthcare

43.37 1.45

Buy Sell

Overview

Share price change

24h

Current

Min

42.68

Max

44.5

Key metrics
By Trading Economics
Income	-116M -66M
Sales	8.4M 393M
P/E Sector Avg	46.967 49.888
EPS	0.38
Profit margin	-16.92
Employees	2,050
EBITDA	-98M -22M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+10.89% upside

Dividends
By Dow Jones
Next Earnings	28 lip 2026

Market Stats
By TradingEconomics
Market Cap	1.4B 7B
Previous open	41.92
Previous close	43.37

News Sentiment

By Acuity

34%

66%

88 / 344 Ranking in Healthcare

Alkermes PLC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 12:22 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Pharma Sector Becoming Bidding Battlefield -- Market Talk

Peer Comparison

Price change

Alkermes PLC Forecast

Price Target

By TipRanks

10.89% upside

12 Months Forecast

Average 45.82 USD 10.89%

High 53 USD

Low 42 USD

Based on 13 Wall Street analysts offering 12 month price targets forAlkermes PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Alkermes PLC - Dist in the past 3 months.

Sentiment

By Acuity

88 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.